The Stride deal wasnt up to the expectation of the market -...

The Stride deal wasnt up to the expectation of the market - small up front and small milestone payments - SC gave shareholders the expectation by putting out a comparable table which he was never going to deliver to.

Had he not given shareholders that expectation then the deal in its self would have seen the sp rise.

The deal in its self is more than likely the best we can hope for - now we need Teva to get marketing approval for Zolpimist and Eddingpharm to conduct the trial required and then move to get approval as well.

They also need to give the market an update on how they are progressing with the Zolpimist MAA for Australia its over two years since they said they were preparing the dossier which forms part of the MAA.

Is it the cost which is holding them back would be a question to ask